(NASDAQ: CGEN) Compugen's forecast annual revenue growth rate of -24.34% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.99%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.34%.
Compugen's revenue in 2026 is $72,656,000.On average, 7 Wall Street analysts forecast CGEN's revenue for 2026 to be $908,023,477, with the lowest CGEN revenue forecast at $201,593,882, and the highest CGEN revenue forecast at $1,650,100,770. On average, 7 Wall Street analysts forecast CGEN's revenue for 2027 to be $1,934,715,022, with the lowest CGEN revenue forecast at $37,066,042, and the highest CGEN revenue forecast at $4,888,746,203.
In 2028, CGEN is forecast to generate $2,978,143,020 in revenue, with the lowest revenue forecast at $1,343,644,028 and the highest revenue forecast at $5,104,712,633.